RadNet (RDNT) Panoramica del titolo
RadNet, Inc. insieme alle sue consociate, fornisce servizi di diagnostica per immagini ambulatoriale negli Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
RDNT Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di RadNet, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$76.35 |
| Massimo di 52 settimane | US$85.84 |
| Minimo di 52 settimane | US$50.82 |
| Beta | 1.38 |
| Variazione di 1 mese | 24.33% |
| Variazione a 3 mesi | 45.73% |
| Variazione di 1 anno | 13.20% |
| Variazione a 3 anni | 156.81% |
| Variazione a 5 anni | 149.92% |
| Variazione dall'IPO | 7,535.00% |
Notizie e aggiornamenti recenti
Seeking Alpha • Aug 12
RadNet: Imaging And AI Keep The Bull Case Intact
Summary RDNT's advanced imaging mix is expanding. I think this will continue to support its improving revenue quality and margins. RDNT's joint ventures across healthcare systems also help it deepen its integration across customers' workflows. DeepHealth is RDNT's second growth leg, as it pairs external software sales with internal workflow efficiencies. Gleamer also creates more opportunities to monetize AI across RDNT's own imaging solutions portfolio. As such, I think RDNT still looks quite compelling, especially if you're a long-term bull in this rapidly growing healthcare niche. Read the full article on Seeking Alpha
Nuova narrativa • Aug 12
AI And Advanced Imaging Will Drive Stronger Margins And Earnings Durability
Catalysts About RadNet RadNet operates a large network of outpatient imaging centers and a growing digital health platform focused on radiology AI and enterprise imaging software. What are the underlying business or industry changes driving this perspective?
Aggiornamento narrativa • Aug 11
RDNT: Imaging Expansion And Breast Ultrasound AI Clearance Will Support Earnings
Analysts have increased their RadNet fair value estimate from $89.75 to $92.88, citing higher price targets supported by recent revenue and adjusted EBITDA beats, stronger imaging center trends reflected in raised FY26 guidance, and additional upside potential from the FDA clearance for the DeepHealth breast ultrasound AI solution. Analyst Commentary Recent research on RadNet highlights a mix of optimism on execution and growth, alongside a few valuation and competitive questions that investors should keep in mind.Recent updates
Seeking Alpha • Aug 12
RadNet: Imaging And AI Keep The Bull Case Intact
Summary RDNT's advanced imaging mix is expanding. I think this will continue to support its improving revenue quality and margins. RDNT's joint ventures across healthcare systems also help it deepen its integration across customers' workflows. DeepHealth is RDNT's second growth leg, as it pairs external software sales with internal workflow efficiencies. Gleamer also creates more opportunities to monetize AI across RDNT's own imaging solutions portfolio. As such, I think RDNT still looks quite compelling, especially if you're a long-term bull in this rapidly growing healthcare niche. Read the full article on Seeking AlphaNuova narrativa • Aug 12
AI And Advanced Imaging Will Drive Stronger Margins And Earnings Durability
Catalysts About RadNet RadNet operates a large network of outpatient imaging centers and a growing digital health platform focused on radiology AI and enterprise imaging software. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Aug 11
RDNT: Imaging Expansion And Breast Ultrasound AI Clearance Will Support Earnings
Analysts have increased their RadNet fair value estimate from $89.75 to $92.88, citing higher price targets supported by recent revenue and adjusted EBITDA beats, stronger imaging center trends reflected in raised FY26 guidance, and additional upside potential from the FDA clearance for the DeepHealth breast ultrasound AI solution. Analyst Commentary Recent research on RadNet highlights a mix of optimism on execution and growth, alongside a few valuation and competitive questions that investors should keep in mind.Aggiornamento narrativa • Jun 24
RDNT: Advanced Imaging And AI Platform Expansion Will Support Future Earnings
RadNet's analyst price target has shifted lower by $5 to $65, with analysts pointing to both the recent target cuts from Barclays and B. Riley and ongoing confidence reflected in its inclusion on Jefferies' Franchise Picks list as key context for the revision.Aggiornamento narrativa • Jun 06
RDNT: Advanced Imaging And AI Execution Will Support Future Earnings
Narrative Update: RadNet The updated analyst price target for RadNet has shifted modestly lower to around $90 per share. This reflects analysts’ recalibration of fair value and discount rate assumptions, while also acknowledging continuing support from recent research that highlights the stock’s inclusion in high-conviction lists and its relative strength in advanced volume growth and imaging pricing versus peers.Articolo di analisi • May 14
Analysts Have Made A Financial Statement On RadNet, Inc.'s (NASDAQ:RDNT) First-Quarter Report
Last week, you might have seen that RadNet, Inc. ( NASDAQ:RDNT ) released its quarterly result to the market. The early...Aggiornamento narrativa • May 07
RDNT: Imaging Platform Execution And New Idaho Venture Will Support Future Earnings
Analysts have trimmed their fair value estimate for RadNet by $0.50 to $89.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E after recent Street research, including a lower $4 price target from B. Riley and an upgrade of Lumexa Imaging at Raymond James.Aggiornamento narrativa • Apr 23
RDNT: Sector Sentiment Tailwinds Will Support Future Earnings Visibility
Analysts have trimmed their price target on RadNet by $2 to reflect slightly updated assumptions on fair value, future P/E and operating metrics, while incorporating recent Street research that highlights improved sentiment following the Raymond James upgrade of Lumexa Imaging. Analyst Commentary Bullish Takeaways Bullish analysts view the recent upgrade of Lumexa Imaging as a supportive read-through for sentiment around diagnostic imaging.Aggiornamento narrativa • Apr 08
RDNT: Outpatient Imaging Shift Will Support Future Earnings Visibility
RadNet's analyst price target now stands at $92. Analysts cite outpatient diagnostic imaging growth drivers, Medicare reimbursement support, potential capital deployment, and an AI ramp as key reasons for maintaining this level.Aggiornamento narrativa • Mar 25
RDNT: Outpatient Imaging Shift And AI Adoption Will Drive Future Upside
Analysts kept their $92 price target for RadNet unchanged, citing what they see as attractive long term growth drivers in outpatient diagnostic imaging, reasonable 2025 to 2028 company targets, supportive Medicare reimbursement trends, potential capital deployment benefits, and expected AI contributions. Analyst Commentary Bullish Takeaways Bullish analysts view outpatient diagnostic imaging as an attractive subsector, with hospital to outpatient shifts and growing demand for advanced imaging seen as key growth drivers that support RadNet's long term story and current valuation framework.Aggiornamento narrativa • Mar 09
RDNT: Outpatient Imaging Shift And AI Ramp Will Support Future Upside
Analysts have raised their price target on RadNet from $91.75 to $92.38. The updated target reflects revised assumptions that incorporate higher projected revenue growth, a lower profit margin outlook, and a higher future P/E multiple supported by recent bullish Street research on outpatient imaging and AI benefits.Aggiornamento narrativa • Feb 22
RDNT: Outpatient Imaging Shift And AI Adoption Will Support Future Upside
Analysts have trimmed their implied future P/E assumption for RadNet, leading to a slightly lower blended price target of about $97 vs. roughly $102 previously.Aggiornamento narrativa • Feb 08
RDNT: Outpatient Imaging Shift And AI Breast Screening Will Support Upside
Analysts have raised their price target on RadNet to about $92, reflecting confidence in the outpatient diagnostic imaging segment and the company's 2025 to 2028 targets, including expected benefits from improved Medicare rates, potential capital deployment, and increasing AI contributions. Analyst Commentary Recent research reflects a generally constructive tone on RadNet, with several firms lifting price targets into the high US$80s to low US$90s range and highlighting both the core imaging business and longer term AI potential.Aggiornamento narrativa • Jan 24
RDNT: Outpatient Imaging Shift And AI Breast Screening Will Drive Upside
Analysts lifted their price target on RadNet to about US$91.75 from roughly US$91.71, reflecting recent coverage that highlights outpatient imaging growth drivers, supportive Medicare reimbursement, capital deployment options, and potential contributions from artificial intelligence (AI). Analyst Commentary Recent Street research on RadNet focuses on outpatient imaging growth, long term targets and the role of AI and capital allocation in supporting the current valuation framework.Aggiornamento narrativa • Jan 09
RDNT: Outpatient Imaging And AI Adoption Will Drive Future Outperformance
Analysts have raised their price target on RadNet to about US$92, citing what they view as reasonable 2025 to 2028 goals, supportive Medicare reimbursement trends, potential capital deployment upside, and growing contributions from AI and outpatient imaging demand. Analyst Commentary Recent research has focused on how RadNet's outpatient imaging footprint, AI initiatives, and long term financial targets could support its valuation and growth ambitions.Aggiornamento narrativa • Dec 13
RDNT: Integrated Offerings And Margin Expansion Will Drive Future Outperformance
Analysts have modestly increased their price target on RadNet, citing stronger long term growth and margin expansion prospects highlighted at the recent investor day and reflected in updated fair value estimates rising from about $91.71 to roughly $92.50 per share, alongside reaffirmed expectations for double digit revenue growth and mid teens EBITDA expansion. Analyst Commentary Bullish analysts highlight that the updated 2028 targets for double digit revenue growth and margin expansion underpin a durable mid teens EBITDA growth profile, which they view as supportive of further multiple expansion from current levels.Aggiornamento narrativa • Nov 28
RDNT: Sustained Demand And Integrated Offerings Will Drive Future Outperformance
Analysts have raised their price target for RadNet from approximately $87 to $93, citing higher revenue growth expectations and confidence in the company’s integrated offerings and sustained demand. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for RadNet, citing encouraging revenue growth expectations and confidence in the company’s ability to deliver sustained margin expansion.Articolo di analisi • Nov 14
Earnings Miss: RadNet, Inc. Missed EPS By 65% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that RadNet, Inc. ( NASDAQ:RDNT ) filed its third-quarter result this time last week...Aggiornamento narrativa • Nov 13
RDNT: Momentum Will Accelerate From Surging Demand And Integrated Offerings
RadNet’s analyst price target has increased from $80.57 to $86.67. This reflects confidence from analysts who cite strong demand, integrated offerings, and positive industry momentum as key drivers.Aggiornamento narrativa • Oct 30
RDNT: Imaging Center Demand And Digital Health Will Drive Measured Upside Potential
Analysts have increased their price target for RadNet from $74 to $81. They cite strong core imaging center demand and ongoing investments in digital health as key factors for the optimistic outlook.Aggiornamento narrativa • Oct 15
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet's analyst price target has been raised from $79.29 to $80.57 per share. This change reflects analysts' optimism amid strong imaging center demand, ongoing digital health investments, and potential M&A opportunities.Aggiornamento narrativa • Sep 19
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet’s consensus price target has risen to $79.29 as analysts cite robust imaging center demand, expanding service opportunities, strong digital health investments, and confidence in management’s strategic execution. Analyst Commentary Robust core imaging center demand trends indicate sustained growth potential.Articolo di analisi • Sep 12
RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Aggiornamento narrativa • Sep 04
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
Driven by robust imaging center demand, growth opportunities, and strong digital health investments, RadNet’s consensus analyst price target held steady at $77.43. Analyst Commentary Robust core imaging center demand trends highlighted in recent management meetings.Seeking Alpha • Mar 11
RadNet: On The Sidelines For Now
Summary RDNT's stock performance has been lackluster, with only an 8.8% increase over the past year, currently trading at $50 per share. Despite decent fundamentals, including steady revenue growth and strong operating cash flow, RDNT faces risks from wage increases and weather-related disruptions. Recent market overreaction to temporary weather impacts presents a potential rebound opportunity, but the projected 8.6% return does not justify the investment risk. I rate RDNT as neutral due to uncertainties in revenue growth and bottom-line pressures, suggesting better opportunities elsewhere with more favorable risk-reward profiles. Read the full article on Seeking AlphaSeeking Alpha • Oct 02
RadNet: Secular Tailwinds Underpinned By AI Monetization Prospects
Summary RadNet, the largest US diagnostic imaging operator, projects $1.8bn in 2024 revenue, driven by AI and Digital Health growth, and expanding imaging centers. Strong Q2 results with 13.9% revenue growth and 19.7% EBITDA increase, fueled by AI advancements and new imaging center openings. Future growth catalysts include market shifts to freestanding centers, increasing importance of joint ventures, and capital deployment for acquisitions and new facilities. Digital Health and AI initiatives, like DeepHealth OS and EBCD, are expected to drive significant revenue and margin expansion. Read the full article on Seeking Alpha
Nuova narrativa • Aug 30
Expanding Imaging Modalities And AI Integration Signal Strong Future Growth In Healthcare Sector
Expansion into advanced imaging and integration of AI technologies aim at boosting revenue through higher reimbursement rates and operational efficiencies.Seeking Alpha • Aug 24
RadNet: Growth In Operating Earnings Off Very Little Incremental Capital
Summary RDNT stock is up 10% since my June publication following a strong set of quarterly numbers in its Q2 FY'24 earnings. Management continue executing on the growth route, recycling funds into new store openings. Same-store procedure volumes continue to ratchet higher, evidencing increased utilization of its legacy base. Net-net, reiterate buy. Read the full article on Seeking AlphaSeeking Alpha • Jun 05
RadNet: Qualified Growth Route, Still Undervalued
Summary RadNet, Inc. shares continue to show strength, having compounded by 184% since 2022. Q1 FY 2024 earnings showed growth in the Digital Health segment and increased MRI, CT, and PET/CT volumes. Management has increased its outlook on full-year revenues and projects $1.67-$1.7 billion in revenue for the year. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
RadNet, Inc. Stock Price Is More Vigorous Than Its Valuation
Summary RadNet, Inc. is assessed as a Buy opportunity especially on price dips for retail value investors; watch its valuation and growth ratings. The company's share price has seen significant growth recently but may drop due to volatility and potential missed estimates. RadNet is at the forefront of the movement to bring diagnostic imaging services out of hospitals, offering lower costs and increased accessibility. Read the full article on Seeking AlphaRendimenti per gli azionisti
| RDNT | US Healthcare | US Mercato | |
|---|---|---|---|
| 7D | 5.5% | 0.2% | 1.7% |
| 1Y | 13.2% | 32.8% | 20.0% |
Ritorno vs Industria: RDNT ha avuto una performance inferiore rispetto al US Healthcare che ha registrato un rendimento 32.8 % nell'ultimo anno.
Rendimento vs Mercato: RDNT ha avuto una performance inferiore al mercato US che ha registrato un rendimento 20 % nell'ultimo anno.
Volatilità dei prezzi
| RDNT volatility | |
|---|---|
| RDNT Average Weekly Movement | 6.3% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: RDNT non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di RDNT è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1981 | 9,060 | Howard Berger | www.radnet.com |
RadNet, Inc. insieme alle sue controllate, fornisce servizi di diagnostica per immagini ambulatoriale negli Stati Uniti e a livello internazionale. L'azienda opera in due segmenti, Imaging Centers e Digital Health. I suoi servizi comprendono risonanza magnetica, tomografia computerizzata, tomografia a emissione di positroni, medicina nucleare, mammografia, ecografia, radiologia diagnostica, fluoroscopia e altre procedure correlate, nonché servizi di imaging multimodale.
RadNet, Inc. Riepilogo dei fondamenti
| RDNT statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$6.08b |
| Utili (TTM) | -US$21.12m |
| Ricavi(TTM) | US$2.27b |
2.6x
Rapporto P/S-284.5x
Rapporto P/ERDNT è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| RDNT Conto economico (TTM) | |
|---|---|
| Ricavi | US$2.27b |
| Costo del fatturato | US$1.88b |
| Profitto lordo | US$392.17m |
| Altre spese | US$413.28m |
| Utili | -US$21.12m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.27 |
| Margine lordo | 17.28% |
| Margine di profitto netto | -0.93% |
| Rapporto debito/patrimonio netto | 95.6% |
Come si è comportato RDNT nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/14 00:25 |
| Prezzo dell'azione a fine giornata | 2026/08/14 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
RadNet, Inc. è coperta da 12 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Sarah James | Barclays |
| Andrew Mok | Barclays |
| Yuan Zhi | B. Riley Securities, Inc. |